CRISPR Therapeutics Shares Slide as Post-Earnings Concerns Persist

CRISPR Therapeutics AG (CRSP) is currently trading down -5.18% at $56.89, significantly underperforming the broader S&P 500, which is down -0.82% today. This sharp decline comes amidst a lack of fresh, specific negative news directly impacting the company on Thursday, March 5, 2026. Instead, the move appears to be a continuation of negative sentiment stemming from its recent financial performance and underlying technical factors.

The most recent significant company-specific news dates back to its fourth-quarter and full-year 2025 earnings report, released on February 12, 2026. CRISPR Therapeutics reported an earnings per share (EPS) loss of -$1.37, missing analysts' consensus estimates of -$1.15. Furthermore, quarterly revenue plummeted 97.8% year-over-year to just $0.86 million, falling well short of the $4.72 million consensus estimate. While the company has highlighted ongoing progress with its pipeline and the commercialization of CASGEVY, the world's first approved CRISPR-based therapy, these substantial financial misses continue to weigh on investor confidence.

Adding to the downward pressure is CRISPR Therapeutics' elevated short interest. As of February 13, 2026, short interest stood at 22.64 million shares, representing between 24.59% and 26.45% of the public float, with a substantial 13.2 days to cover. Such a high level of short interest makes a stock particularly vulnerable to sharp declines when selling momentum builds, as short sellers capitalize on negative sentiment. Recent insider selling activity has also been noted, with the CEO and General Counsel executing sales in January and February 2026, which could further contribute to a cautious investor outlook.

Despite the recent price action, analyst sentiment on CRSP remains largely positive for the long term. The stock currently holds a consensus rating of 'Buy' or 'Moderate Buy' from a significant number of analysts, with average price targets ranging from approximately $70 to $84, suggesting considerable upside from current levels. However, these longer-term outlooks do not always prevent short-term volatility driven by market dynamics and lingering concerns. The biotechnology sector, in which CRISPR Therapeutics operates, has seen mixed signals recently, but CRSP's pronounced drop today suggests company-specific factors are primarily at play, rather than a broad sector downturn.

Looking ahead, investors will be closely watching for updates on CRISPR Therapeutics' strategic priorities and anticipated 2026 milestones, including global CASGEVY commercialization and pediatric regulatory submissions in the first half of the year, as well as progress on its extensive in vivo and cell therapy pipeline.